Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  AUSTRALIAN SECURITIES EXCHANGE LIMITED  >  MGC Pharmaceuticals Ltd    MXC   AU000000MXC6

MGC PHARMACEUTICALS LTD (MXC)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsCalendarCompany 
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweetsMarketScreener Strategies

MGC Pharmaceuticals : MXC partners with Epilepsy Action Australia

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/30/2018 | 02:21am CET

30 October 2018

ASX Code: MXC

MXC partner with Epilepsy Action Australia to launch medical cannabis education platform

  • MXC collaborates with Epilepsy Action Australia to design and build an online education platform for medicinal cannabis and epilepsy

  • The Platform will be designed for the everyday use of healthcare professionals and epilepsy patients, as a gateway to knowledge on epilepsy and access to medical cannabis treatments

  • Showcases MXC's commitment to providing education and improving the lives of epilepsy sufferers

  • MXC committed to finance phase one of the project with Epilepsy Action Australia

  • Phase one of the project will be presented at the CannaTech conferences, hosted in Sydney between 28th - 30th October

MGC Pharmaceuticals Ltd (ASX: MXC or "the Company") is pleased to announce it has partnered with Epilepsy Action Australia (EAA) to create an online platform dedicated to providing information and education on medicinal cannabis and epilepsy.

The platform will take the form of an EAA website and is designed as an effective online educational tool that provides easily packaged, accessible, user-friendly information about epilepsy and medicinal cannabis.

The platform is intended for healthcare practitioners and patients suffering from epilepsy and will provide information via its 'Get Educated" and 'Get Access' portals. These portals will consist of news, research breakthroughs and information on how to access medicinal cannabis treatments and clinical trials.

The website will be populated by epilepsy and pharmaceutical experts and phase one of the project will be presented at the CannaTech conference on the 28th - 30th October in Sydney.

The Company has committed to finance phase one of the EAA project and design and development has already commenced.

1

-

2

Roby Zomer, Co-founder and Managing Director, MGC Pharmaceuticals commented

"I am delighted to announce we have everything in place to begin the design and development of our education project in collaboration with Epilepsy Action Australia. We are dedicated to improving the lives of epilepsy sufferers and will continue to research, develop and progress the clinical epilepsy market."

Carol Ireland, CEO and Managing Director of Epilepsy Action Australia commented

"Epilepsy patients are always looking for reliable and trusted information and new research and we have noticed an influx of patients seeking information on medical cannabis. Partnering with MGC Pharma and launching the platform will allow us to provide patients with a portal to access all the information they need to help them better understand what options and alternatives are available to them."

--Ends-

For further information, please contact:

Media Enquiries

MGC Pharmaceuticals Ltd

Rosa Smith

Brett Mitchell

Media and Capital Partners

Executive Chairman

+61 457 305 047

+61 8 6382 3390

Rosa.smith@mcpartners.com.au

info@mgcpharma.com.au

About MXC

MGC Pharmaceuticals Ltd (ASX: MXC) is an EU based BioPharma company with many years of technical clinical and commercial experience in the medical cannabis industry. The Company's founders were key figures in the global medical cannabis industry and the core business strategy is to develop and supply high quality Cannabinoids based pharmaceuticals products for the growing demand in the medical markets in Europe, North America and Australasia.

Follow us through our social media channels

2

-

2

Disclaimer

MGC Pharmaceuticals Ltd. published this content on 30 October 2018 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 30 October 2018 01:21:01 UTC

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MGC PHARMACEUTICALS LTD
11/13MGC PHARMACEUTICALS : Definitive Agreement Signed for Sale of MGC Derma
PU
10/31MGC PHARMACEUTICALS : Appendix 4G and Corporate Governance Statement
PU
10/30MGC PHARMACEUTICALS : MXC partners with Epilepsy Action Australia
PU
10/26MGC PHARMACEUTICALS : September Quarterly Activity and Cashflow Report
PU
10/16MGC PHARMACEUTICALS : Response to ASX Price and Volume Query
PU
10/16MGC PHARMACEUTICALS : Pause in Trading
PU
10/12MGC PHARMACEUTICALS : gains tick of approval cannabis epilepsy drug
AQ
10/04MGC PHARMACEUTICALS : Derma - CannaGlobal Transaction Update
PU
08/29MGC PHARMACEUTICALS : gets ethics nod for marijuana-based dementia drug
AQ
07/18MGC PHARMACEUTICALS : Change of Director's Interest Notice - Appendix 3Y
PU
More news
News from SeekingAlpha
07/24Horizons Emerging Marijuana Growers ETF HMJR - 2018 Q2 Update 
06/26WEEKLY CANNABIS REPORT : Molson Coors, Shopify, Tilray, Legal Sales 
06/11WEEKLY CANNABIS REPORT : Legalization Is Here, What's Next? 
05/29WEEKLY CANNABIS REPORT : $2.1 Billion Shorts, Hydropothecary, Invictus 
05/23COMPLETE CANNABIS GUIDE #4 : Provincial Regulations In Canada 
Chart MGC PHARMACEUTICALS LTD
Duration : Period :
MGC Pharmaceuticals Ltd Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MGC PHARMACEUTICALS LTD
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Managers
NameTitle
Roby Zomer Managing Director
Brett Anthony Mitchell Executive Chairman
Nativ Segev Director
Ross Walker Non-Executive Director
Kate Sainty Joint Secretary
Sector and Competitors
1st jan.Capitalization (M$)
MGC PHARMACEUTICALS LTD-53.93%36
JOHNSON & JOHNSON4.49%391 542
PFIZER20.13%252 358
NOVARTIS6.38%222 056
ROCHE HOLDING LTD.1.54%214 508
MERCK AND COMPANY35.17%197 785